Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

BACKGROUND: We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A). The purpose of this study was to evaluate the safety and pharmacokinetics of dep...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Neuro Oncol
Main Authors: Gan, Hui K, Reardon, David A, Lassman, Andrew B, Merrell, Ryan, van den Bent, Martin, Butowski, Nicholas, Lwin, Zarnie, Wheeler, Helen, Fichtel, Lisa, Scott, Andrew M, Gomez, Erica J, Fischer, JuDee, Mandich, Helen, Xiong, Hao, Lee, Ho-Jin, Munasinghe, Wijith P, Roberts-Rapp, Lisa A, Ansell, Peter J, Holen, Kyle D, Kumthekar, Priya
פורמט: Artigo
שפה:Inglês
יצא לאור: Oxford University Press 2018
נושאים:
Clinical Investigations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961429/
https://ncbi.nlm.nih.gov/pubmed/29077941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox202
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים